Biosimilars

 

While We Await Vaccine Progress, We Can Trust in Generic Drugs

February 01, 2021

Generic drugs account for 90% of the prescriptions filled in the United States. They are the backbone of healthcare providers’ treatment protocol and they are remarkably cost effective: despite being 90% of the prescriptions filled, generics account for only 20% of drug spending.

When Will Biosimilars Start Making a Serious Difference in Oncology?

August 05, 2020

It's early days yet because patent and other issues have kept FDA-approved biosimilars off the market, but Gary Lyman, M.D., M.P.H.. of the Fred Hutchinson Cancer Research Center says there's evidence of some effect on the price of cancer supportive drugs.